NCT00406172撤回3 期
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
Asociación para Evitar la Ceguera en México2 个研究点 分布在 1 个国家开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 2
研究概览
简要总结
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pseudophakic eyes with macular edema
排除标准
- •Other retinopathies
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Intravitreal bevacizumab(Avastin) for macular edema secondary to uveitis: 1 year results of a prospective pilot studyMacular edema secondary to uveitis.Other specified retinal disordersIRCT138902113846N1Shiraz University of Medical Sciences30
Unknown
2 期
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of PrematurityRetinopathy of PrematurityNCT00622726The University of Texas Health Science Center, Houston150
已完成
不适用
Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin)diabetic retinopathy central retinal vein occulusion, neovascular glaucomaJPRN-UMIN000012248ational Center for Global Health and Medicine, Kohnodai Hospital20
已完成
4 期
Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic RetinopathyProliferative Diabetic RetinopathyNCT01025934University of Campania "Luigi Vanvitelli"
Unknown
不适用
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50